243 related articles for article (PubMed ID: 35000236)
1. Characterizing the relationships between patient-reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib.
Winnette R; Banerjee A; Sikirica V; Peeva E; Wyrwich K
J Eur Acad Dermatol Venereol; 2022 Apr; 36(4):602-609. PubMed ID: 35000236
[TBL] [Abstract][Full Text] [Related]
2. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
King B; Guttman-Yassky E; Peeva E; Banerjee A; Sinclair R; Pavel AB; Zhu L; Cox LA; Craiglow B; Chen L; Banfield C; Page K; Zhang W; Vincent MS
J Am Acad Dermatol; 2021 Aug; 85(2):379-387. PubMed ID: 33757798
[TBL] [Abstract][Full Text] [Related]
3. Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers.
Guttman-Yassky E; Pavel AB; Diaz A; Zhang N; Del Duca E; Estrada Y; King B; Banerjee A; Banfield C; Cox LA; Dowty ME; Page K; Vincent MS; Zhang W; Zhu L; Peeva E
J Allergy Clin Immunol; 2022 Apr; 149(4):1318-1328. PubMed ID: 34863853
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a Trial.
King B; Guttman-Yassky E; Peeva E; Banerjee A; Zhu L; Zhu H; Cox LA; Vincent MS; Sinclair R
JID Innov; 2022 Nov; 2(6):100156. PubMed ID: 36277481
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial.
Hordinsky M; Hebert AA; Gooderham M; Kwon O; Murashkin N; Fang H; Harada K; Law E; Wajsbrot D; Takiya L; Zwillich SH; Wolk R; Tran H
Pediatr Dermatol; 2023; 40(6):1003-1009. PubMed ID: 37455588
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.
King B; Zhang X; Harcha WG; Szepietowski JC; Shapiro J; Lynde C; Mesinkovska NA; Zwillich SH; Napatalung L; Wajsbrot D; Fayyad R; Freyman A; Mitra D; Purohit V; Sinclair R; Wolk R
Lancet; 2023 May; 401(10387):1518-1529. PubMed ID: 37062298
[TBL] [Abstract][Full Text] [Related]
7. Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes.
Renert-Yuval Y; Correa da Rosa J; Garcet S; Pavel AB; Bares J; Chima M; Hawkes JE; Gilleaudeau P; Sullivan-Whalen M; Singer GK; Krueger JG; Guttman-Yassky E
Br J Dermatol; 2022 Oct; 187(4):539-547. PubMed ID: 35656793
[TBL] [Abstract][Full Text] [Related]
8. Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata.
Eisman S; Sinclair R
Expert Opin Investig Drugs; 2021 Dec; 30(12):1169-1174. PubMed ID: 34826225
[TBL] [Abstract][Full Text] [Related]
9. Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study.
Thaçi D; Tziotzios C; Ito T; Ko J; Karadağ AS; Fang H; Edwards RA; Bonfanti G; Wolk R; Tran H; Law E
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2621-2634. PubMed ID: 37707764
[TBL] [Abstract][Full Text] [Related]
10. LITFULO
Gupta AK; Ravi SP; Vincent K; Abramovits W
Skinmed; 2023; 21(6):434-438. PubMed ID: 38051245
[TBL] [Abstract][Full Text] [Related]
11. A plain language summary on ritlecitinib treatment for adults and adolescents with alopecia areata.
King B; Zhang X; Harcha WG; Szepietowski JC; Shapiro J; Lynde C; Mesinkovska NA; Zwillich SH; Napatalung L; Wajsbrot D; Fayyad R; Freyman A; Mitra D; Purohit V; Sinclair R; Wolk R
Immunotherapy; 2023 Oct; 15(14):1093-1103. PubMed ID: 37403610
[TBL] [Abstract][Full Text] [Related]
12. Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial.
Peeva E; Guttman-Yassky E; Banerjee A; Sinclair R; Cox LA; Zhu L; Zhu H; Vincent M; King B
J Am Acad Dermatol; 2022 Aug; 87(2):390-393. PubMed ID: 34915057
[No Abstract] [Full Text] [Related]
13. Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata.
Ramírez-Marín HA; Tosti A
Drug Des Devel Ther; 2022; 16():363-374. PubMed ID: 35210753
[TBL] [Abstract][Full Text] [Related]
14. Validation of the Alopecia Areata Patient Priority Outcomes (AAPPO) Questionnaire in Adults and Adolescents with Alopecia Areata.
Wyrwich KW; Winnette R; Bender R; Gandhi K; Williams N; Harris N; Nelson L
Dermatol Ther (Heidelb); 2022 Jan; 12(1):149-166. PubMed ID: 34846634
[TBL] [Abstract][Full Text] [Related]
15. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
King B; Soung J; Tziotzios C; Rudnicka L; Joly P; Gooderham M; Sinclair R; Mesinkovska NA; Paul C; Gong Y; Anway SD; Tran H; Wolk R; Zwillich SH; Lejeune A
Am J Clin Dermatol; 2024 Mar; 25(2):299-314. PubMed ID: 38263353
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata: A Pooled Analysis of the BRAVE-AA1 and BRAVE-AA2 Trials.
Ko JM; Mayo TT; Bergfeld WF; Dutronc Y; Yu G; Ball SG; Somani N; Craiglow BG
JAMA Dermatol; 2023 Sep; 159(9):970-976. PubMed ID: 37556146
[TBL] [Abstract][Full Text] [Related]
17. Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study.
Sandborn WJ; Danese S; Leszczyszyn J; Romatowski J; Altintas E; Peeva E; Hassan-Zahraee M; Vincent MS; Reddy PS; Banfield C; Salganik M; Banerjee A; Gale JD; Hung KE
Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2616-2628.e7. PubMed ID: 36623678
[TBL] [Abstract][Full Text] [Related]
18. Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review.
Papierzewska M; Waśkiel-Burnat A; Rudnicka L
Clin Drug Investig; 2023 May; 43(5):325-334. PubMed ID: 37138134
[TBL] [Abstract][Full Text] [Related]
19. Exploring Janus kinase inhibitors for alopecia areata: a comprehensive review.
Bushwereb R; Srivastava G
Ital J Dermatol Venerol; 2024 May; ():. PubMed ID: 38780910
[TBL] [Abstract][Full Text] [Related]
20. Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase-4 inhibitors.
Gupta AK; Wang T; Polla Ravi S; Bamimore MA; Piguet V; Tosti A
J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):666-679. PubMed ID: 36478475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
